• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    2/8/23 4:15:16 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RPID alert in real time by email
    SC 13G/A 1 tm235737d1_sc13ga.htm SC 13G/A

     

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Schedule 13G

     

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 1)*

     

    Rapid Micro Biosystems, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Title of Class of Securities)

     

    75340L104

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 75340L104Schedule 13GPage 1 of 6

     

    1 Names of Reporting Persons

    Colony Harvest Ltd.
    2 Check the Appropriate Box if a Member of a Group (a) ¨
    (b) ¨
    3

    SEC Use Only 

     

    4 Citizenship or Place of Organization

    Cayman Islands
    Number of Shares
    Beneficially Owned
    by Each Reporting
    Person With
    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    1,622,260

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    1,622,260

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,622,260

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.5%

    12

    Type of Reporting Person

     

    CO

             

     

    CUSIP No. 75340L104Schedule 13GPage 2 of 6

     

    1 Names of Reporting Persons

    Fares Zahir
    2 Check the Appropriate Box if a Member of a Group (a) ¨
    (b) ¨
    3

    SEC Use Only 

     

    4 Citizenship or Place of Organization

    Malaysia
    Number of Shares
    Beneficially Owned
    by Each Reporting
    Person With
    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

    1,622,260

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    1,622,260

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,622,260

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11

    Percent of Class Represented by Amount in Row 9

     

    4.5%

    12

    Type of Reporting Person

     

    IN

             

     

    CUSIP No. 75340L104Schedule 13GPage 3 of 6

     

    ITEM 1.(a)           Name of Issuer:

     

    Rapid Micro Biosystems, Inc. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    1001 Pawtucket Boulevard West, Suite 280, Lowell, MA 01854

     

    ITEM 2.(a)           Name of Person Filing:

     

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

    Colony Harvest Ltd.

    Fares Zahir

     

    (b)Address or Principal Business Office:

     

    The principal business address for the Reporting Persons is 26.03-26.08, Level 26, GTower, No. 199, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia.

     

    (c)Citizenship of each Reporting Person is:

     

    Colony Harvest Ltd. is organized under the laws of the Cayman Islands. Fares Zahir is a citizen of Malaysia.

     

    (d)Title of Class of Securities:

     

    Class A Common Stock, par value $0.01 per share (“Class A Common Stock”).

     

    (e)CUSIP Number:

     

    75340L104

     

    ITEM 3.

     

    Not applicable.

     

    ITEM 4.Ownership.

     

    (a-c)

     

    The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of December 31, 2022, based upon 36,440,906 shares of Class A Common Stock outstanding as of November 7, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.

     

     

    CUSIP No. 75340L104Schedule 13GPage 4 of 6

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class:

       Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

    Sole power to dispose or to direct the disposition

    of:

      

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     
    Colony Harvest Ltd.   1,622,260    4.5%   0    1,622,260    0    1,622,260 
    Fares Zahir   1,622,260    4.5%   0    1,622,260    0    1,622,260 

     

    Colony Harvest Ltd. is the record holder of the shares of Class A Common Stock reported herein. Fares Zahir is the director of Colony Harvest Ltd. and may be deemed to share beneficial ownership over the securities reported herein.

     

    ITEM 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: x

     

    ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    ITEM 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    ITEM 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    ITEM 10.Certification.

     

    Not applicable.

     

     

    CUSIP No. 75340L104Schedule 13GPage 5 of 6

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 8, 2023

     

      Colony Harvest Ltd.

     

    By:/s/ Fares Zahir
    Name:Fares Zahir
    Title:Director

     

      Fares Zahir

     

      /s/ Fares Zahir

     

     

    CUSIP No. 75340L104Schedule 13GPage 6 of 6

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
    99 Joint Filing Agreement (previously filed).

     

     

     

    Get the next $RPID alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPID

    DatePrice TargetRatingAnalyst
    7/28/2025$8.00Buy
    Lake Street
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    8/16/2022Overweight → Neutral
    JP Morgan
    3/7/2022$11.00 → $10.00Equal-Weight
    Morgan Stanley
    2/15/2022$24.00 → $11.00Equal-Weight
    Morgan Stanley
    11/15/2021$26.00 → $24.00Equal-Weight
    Morgan Stanley
    8/9/2021Outperform
    Cowen
    8/9/2021$26.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RPID
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

    Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c

    8/12/25 6:31:30 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.

    $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company's financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. (NASDAQ:TRIN) ("Trinity Capital"). Proceeds from this facility will be used for general c

    8/12/25 6:30:10 AM ET
    $RPID
    $TRIN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Finance: Consumer Services
    Finance

    Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025

    LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for re

    7/31/25 4:15:54 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Rapid Micro Biosystems with a new price target

    Lake Street initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $8.00

    7/28/25 8:29:57 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

    KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

    2/12/25 7:09:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems downgraded by JP Morgan

    JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral

    8/16/22 7:57:15 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    SEC Filings

    View All

    SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

    10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    8/12/25 5:15:39 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    8/12/25 6:33:39 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Rapid Micro Biosystems Inc.

    144 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    7/11/25 3:22:46 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pei Melinda Litherland bought $20,364 worth of shares (20,000 units at $1.02), increasing direct ownership by 58% to 54,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    12/5/24 6:44:47 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Pei Melinda Litherland bought $20,999 worth of shares (20,000 units at $1.05), increasing direct ownership by 140% to 34,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    11/27/24 9:42:03 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Malloy Kirk bought $45,335 worth of shares (50,000 units at $0.91), increasing direct ownership by 350% to 64,300 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    8/9/24 8:36:24 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Spignesi Robert G. Jr. converted options into 50,290 shares and sold $78,979 worth of shares (23,755 units at $3.32), increasing direct ownership by 3% to 970,550 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    7/15/25 4:37:20 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT AND CEO Spignesi Robert G. Jr. converted options into 75,433 shares and sold $116,976 worth of shares (33,688 units at $3.47), increasing direct ownership by 8% to 944,015 units (SEC Form 4)

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    7/10/25 7:43:21 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Bika Dafni

    4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)

    5/27/25 8:31:14 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Financials

    Live finance-specific insights

    View All

    Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results

    Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c

    8/12/25 6:31:30 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025

    LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Tuesday, August 12, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for re

    7/31/25 4:15:54 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Reports First Quarter 2025 Financial Results

    Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma"). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Compa

    5/9/25 7:00:55 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/24 10:04:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    1/22/24 5:28:26 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/23 4:17:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    Leadership Updates

    Live Leadership Updates

    View All

    Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

    LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an

    5/27/25 9:00:22 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

    LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar

    7/18/23 5:20:56 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

    LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S

    5/4/23 4:30:10 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials